Table 1 Clinical-pathological prognostic features of disease
From: Detection methods predict differences in biology and survival in breast cancer patients
Screen-detected (n = 161) vs. Symptomatic (n = 130) | P value | OR adjusted by tumor size | |
|---|---|---|---|
Mean age | 56.33 ± 1.14 vs. 56.73 ± 1.18 | N.S. | 1.03 (0.99-1.05) |
Mean size (cm) | 1.62 + 0.14 vs. 2.68 + 0.15 | p < 0.001 | -- |
Lymph node positive | 22.3% vs. 48.9% | p < 0.001 | 0.54 (0.31-0.95) |
Poorly differentiated tumors | 33.1% vs. 39.7% | N.S. | 0.75 (0.47-1.20) |
ER positive | 87.8% vs. 57.4% | p < 0.001 | 4.76 (2.50-9.09) |
PR positive | 73.1% vs. 36.4% | p < 0.001 | 4.16 (2.43-7.14) |
In situ carcinomas | 11.4% vs.1.5% | p < 0.001 | 6.25 (1.35-33.3) |
Apoptosis | 48.8% vs. 38.5% | N.S. | 1.53 (0.84-2.77) |
Bcl-2 | 78.4% vs. 62.7% | p < 0.01 | 1.92 (1.08-3.44) |
c-erb-B2 | 14.6% vs. 26.3% | p < 0.05 | 0.57 (0.15-0.97) |
Ki67 | 46.7% vs. 52.5% | N.S. | 0.97 (0.57-1.63) |
Delay Diagnosis- treatment (>30 days) | 47.5% vs. 57% | N.S. | 0.75 (0.46-1.25) |